What does the PCOS to PMOS name change mean for women's health research?

The renaming of PCOS to PMOS is the most consequential change in how a major women's health condition has been classified in decades. It is not only a terminology update. It is a signal about how science and medicine understand women's health at a systems level, and it has direct implications for what research gets funded, what treatments get developed, what insurance covers, and how the next generation of women receive care. The name change opens doors that the old name held shut for thirty years.

Why naming a condition shapes its research trajectory

The name a condition carries determines which specialists study it, which funding streams it qualifies for, which endpoints clinical trials measure, and which journals prioritize publishing about it. When PCOS was framed as a polycystic ovary condition, its research home was reproductive medicine. Fertility outcomes were the primary endpoints. The metabolic, cardiovascular, neurological, and psychological dimensions of the condition were secondary concerns in a research landscape organized around the reproductive frame.

The result, over three decades, was a condition that affected more than 170 million women and was associated with significantly elevated risks of type 2 diabetes, cardiovascular disease, fatty liver disease, depression, and sleep apnea, yet whose research funding was dominated by fertility-focused trials. Women living with the metabolic and psychological burden of the condition were largely on the margins of the research agenda that was nominally about them.

According to the Lancet consensus paper, the old name curtailed research and policy framing. That language is precise and consequential. A name that curtails research is a name that has actively limited the scientific knowledge available to guide the care of millions of women.

"Hormone health is not just about fertility. It's your energy, your mood, your inflammation, your metabolic health, your daily wellbeing. The period of time when a woman is trying to conceive is such a small window of her life, and yet that's often the only time this condition ever gets diagnosed or treated. We can do so much better for women."

— Amy Suzanne Upchurch, Founder and CEO of Pink Stork

The research questions PMOS opens up

A name that centers metabolic and endocrine function creates the scientific mandate to ask different questions than a name that centers ovarian cysts. The research questions that become more central under the PMOS framing include: how does insulin resistance in PMOS interact with cardiovascular risk over a woman's lifetime? What are the neurological effects of chronic androgen elevation? How do the metabolic features of PMOS change across perimenopause and menopause? What interventions beyond fertility treatment improve long-term metabolic outcomes?

New genomic research published in Nature Genetics in 2025 had already identified additional genetic pathways linked to PMOS, including mechanisms related to insulin signaling, ovarian function, and inflammatory pathways, as reported by MedBound Times. The PMOS framing gives these findings a more natural home in research literature organized around metabolic and endocrine science rather than reproductive medicine alone.

Dr. Christina Boots of Northwestern's Feinberg School of Medicine stated in CNN that recognizing PMOS as spanning reproductive, mental, and metabolic health may help enhance the number of research dollars and the number of studies directed toward understanding and treating it. Women's health is notoriously underfunded. Accurate naming is one of the most direct levers available to change that.

Policy implications: from classification to coverage

Disease classification systems are not academic abstractions. They determine insurance coverage, public health policy priorities, and the allocation of government research funding. When PMOS is classified as a metabolic and endocrine condition, the policies that govern metabolic and endocrine care become relevant to women with this condition in ways they were not under the reproductive-only framing of PCOS.

The implementation roadmap published alongside the Lancet consensus includes updates to clinical guidelines and international disease classification systems in 195 countries, as documented by Contemporary OB/GYN. As those updates take effect, insurance coverage for metabolic interventions, dietary counseling, cardiovascular monitoring, and insulin-sensitizing therapies becomes more defensible as standard of care rather than supplemental.

The policy shift also matters for public health systems that allocate resources based on disease burden. A condition classified as metabolic and endocrine with cardiovascular consequences competes for resources from different funding streams than a condition classified as reproductive. The broader the classification, the larger the public health case for investment.

"We can't have women dying of preventable things. Especially in a country where we should have the resources to prevent those things."

— Jessica Nazzaro, DO, FACOG, NCMP, Board-Certified OB-GYN and National Certified Menopause Practitioner

What this means for the next generation of women

PMOS can manifest as early as adolescence. Cycle irregularity, acne, and signs of insulin resistance in teenage girls are often dismissed as normal hormonal variation of puberty. Under the PCOS framework, most of those girls would not receive a diagnosis or metabolic evaluation until they sought fertility assistance as adults, if they received one at all.

A name that points toward metabolic and endocrine dysfunction creates the clinical rationale for earlier investigation when adolescent girls present with these features. Earlier identification means earlier metabolic support, earlier management of insulin resistance, and a significantly reduced lifetime burden of the cardiovascular and metabolic consequences that accumulate when the condition goes unaddressed for years.

As Dr. Samantha Ess, ND, has observed, "If we teach women about their bodies and teach them what is actually normal versus what is abnormal, that education can make a real difference earlier on." The PMOS name change is one step toward that kind of early, accurate education being possible across medicine, public health, and school health programs alike.

The National Institutes of Health has articulated a whole-person approach to women's health research, acknowledging that many interconnected factors contribute to health and disease across a woman's lifetime. The PMOS rename is a concrete expression of that principle applied to one of the most common conditions affecting women worldwide.

The advocacy dimension: what women can do

Scientific and policy change of this scale is driven by research, but it is sustained by advocacy. The 22,000 women and health professionals who participated in the global surveys that led to the PMOS renaming were advocates. The patient organizations in the United Kingdom, Australia, the United States, and across Europe that pushed for this change for over a decade were advocates. The women who spent years telling their providers that something was wrong and insisting on answers were advocates.

That advocacy continues. Women can support broader adoption of the PMOS framing by asking their providers to use the updated terminology, by requesting the metabolic screening the new name implies, and by sharing credible information about the name change with other women in their communities who may have been living undiagnosed or under-supported for years.

Rachel Morman, Chair of Verity PCOS UK and a lived experience expert on the global name change process, described the outcome as demanding that this condition be taken as seriously as the long-term, complex health condition it is, according to the Endocrine Society. That demand now has a name to support it.

For a complete picture of what the PMOS name change means across diagnosis, treatment, and advocacy, see our full series: what PMOS is and why PCOS just got renamed, why so many women with PCOS went undiagnosed, what PMOS and insulin resistance have to do with each other, and how the name change will affect diagnosis and treatment.

Frequently asked questions

Why does the name of a medical condition matter for research funding?

The name of a condition determines which specialists study it, which clinical endpoints are prioritized in trials, and which funding streams it qualifies for. When PCOS was named as a reproductive condition, fertility outcomes dominated research. PMOS, named as metabolic and endocrine, opens the condition to research funding from cardiology, endocrinology, and metabolic health streams that were not previously central to its scientific community.

Will the PMOS name change lead to new treatments?

Over time, yes. A metabolic framing of the condition creates the rationale for developing and testing treatments that address insulin resistance and androgen production upstream, rather than managing downstream symptoms. GLP-1 receptor agonists are one area of active interest, with emerging data on their relevance to metabolic features of PMOS. More research, framed by the new name, is expected to expand the treatment landscape beyond hormonal birth control and fertility protocols.

How does PMOS affect adolescents and why does early identification matter?

PMOS can manifest in adolescence with cycle irregularity, acne, and signs of insulin resistance. Under the old PCOS framework, most adolescent girls were not evaluated for the condition unless symptoms were severe. Earlier identification under the PMOS framing, which creates the rationale for metabolic screening in adolescent girls with relevant symptoms, could significantly reduce the long-term metabolic burden of the condition by allowing earlier intervention.

What role did patient advocacy play in the PMOS name change?

Patient advocacy was central to the process. More than 22,000 patients and health professionals participated in the global surveys that informed the new name. Patient organizations in multiple countries were formal participants in the consensus process. The primary outcome patients said they wanted from a new name was stigma reduction, followed by scientific accuracy. Both are reflected in PMOS.

Will PMOS be covered differently by insurance than PCOS?

As disease classification systems are updated in the coming years to reflect PMOS as a metabolic and endocrine condition, the case for insurance coverage of metabolic interventions, including dietary counseling, insulin-sensitizing therapies, and cardiovascular monitoring, becomes more defensible as standard care. The full impact on insurance coverage will unfold over the transition period as classification updates take effect across different healthcare systems.

What is the most important thing women should know about the PMOS name change?

That it is not cosmetic. After 14 years of international effort and input from 22,000 stakeholders, a name was chosen that accurately describes a condition affecting more than 170 million women as what it actually is: a whole-body endocrine and metabolic condition. That accuracy changes what care women can ask for, what research will be funded, and how medicine will approach this condition for the next generation of women and girls.

† These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare provider before starting any new supplement, especially during pregnancy, breastfeeding, or while managing a medical condition. Keep out of reach of children.